#Bulgaria Today with @LHreports & partners, we release the first visual evidence of an asylum seeker being hit with live ammunition on the #EU border. His name is Abdullah El Rüstüm and I have met him last October in #Istanbul.
A THREAD 🧵
For almost 8 months, the OLAF report on #Frontex has been kept strictly confidential. Today we're publishing it in full.
It shows how @Frontex made sure human rights violations would not be witnessed, documented, investigated or accounted for.
https://t.co/cNDab4LNRI
Had a great time at the @PET_Symposium in Sydney, where I presented my first publication about expert interviews on collection, usage and privacy of mobility data in practice. 📄
You can find the paper here:
https://t.co/l9udvNbRSJ
My first co-edited book arrived yesterday. It has lots of cool articles on encounters with #AI. You can get it everywhere you usually get books ;) Feel free to DM me for more infos. #philosophy#phenomenology#technology#lifeworld
Preparation done, presentation uploaded, speaker ready...
Looking forward to presenting our work on why the occlusion side of LVO stroke matters for our patients at #RSNA21. See you in room N228 at 3pm. @YaleRadiology
@SamPayabvash Thank you so much for being our mentor, your unwavering support and kindness along this journey. Really couldn't have wished for more. Looking forward to many more years of collaboration and - even more important - friendship!
Huge thanks to @SamPayabvash for his kind and tireless support and mentorship along the way, you made this possible. Also huge thanks to all the others who contributed to this project along the way. @GuidoFalconeMD@sheth_kevin @VinceMadai and many more.
end/
Proudly - and a bit anxiously - presenting my premier first authorship paper on differences in final infarct volume and clinical outcome in patients with LVO stroke after mechanical thrombectomy.
1/
https://t.co/ai6w5rtJlR
In summary, our findings provide novel insights into spacial distribution of final infarct lesions in relation to different clinical variables and may reinforce the need for more nuanced ET eligibility criteria, taking LVO side into consideration along with symptom severity.
6/